These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10443264)

  • 1. [Clinical researchers and the pharmaceutical industry. Usefulness and need for an independent steering committee].
    Van Gijn J; Algra A
    Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1477-9. PubMed ID: 10443264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The GCP directive--consequences for clinical drug research].
    Gluud CN
    Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research results should be freely accessible!-- Case reports demonstrate obstacles to contact with drug industry].
    Eliasson M; Bergqvist D
    Lakartidningen; 2001 Sep; 98(37):3913-6. PubMed ID: 11586830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Public GCP unit--experiences from the Aarhus University Hospital].
    Jørgensen A; Rønnow IL; Nexø E
    Ugeskr Laeger; 2003 Apr; 165(16):1667-9. PubMed ID: 12756826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and quality in clinical trials. Requirements to the investigator site. European Economic Community.
    Friederichs E; Spitzer SG; Bach R
    Arzneimittelforschung; 1994 Feb; 44(2):182-4. PubMed ID: 8147953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How pharmaceutical industry funding affects trial outcomes: causal structures and responses.
    Sismondo S
    Soc Sci Med; 2008 May; 66(9):1909-14. PubMed ID: 18299169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences with GLP/GCP from the pharmaceutical industry's viewpoint.
    Legler UF
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):233-6. PubMed ID: 8361261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analgesia and anesthesia for neonates: study design and ethical issues.
    Anand KJ; Aranda JV; Berde CB; Buckman S; Capparelli EV; Carlo WA; Hummel P; Lantos J; Johnston CC; Lehr VT; Lynn AM; Maxwell LG; Oberlander TF; Raju TN; Soriano SG; Taddio A; Walco GA
    Clin Ther; 2005 Jun; 27(6):814-43. PubMed ID: 16117988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners.
    Geller NL; Pocock SJ
    Biometrics; 1987 Mar; 43(1):213-23. PubMed ID: 3567306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical trials on medical products for human use in the case of acutely incapacitated patients within the fields of neurology and neurosurgery; implications of the new European legislation].
    Kompanje EJ; Maas AI; Dippel DW
    Ned Tijdschr Geneeskd; 2003 Aug; 147(33):1585-9. PubMed ID: 12951727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach.
    Berry DA; Ho CH
    Biometrics; 1988 Mar; 44(1):219-27. PubMed ID: 3358990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
    Huang SM; Temple R; Throckmorton DC; Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Good clinical practice. Reorientation in clinical research. European Society for Good Clincial Practice].
    Spitzer S; Kiesewetter H; Bach R; Gutensohn J; Jung F; Schieffer H; Kleinsorge H
    Dtsch Med Wochenschr; 1993 Jun; 118(22):838-43. PubMed ID: 8504726
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
    James JS
    AIDS Treat News; 1998 Mar; (No 290):8. PubMed ID: 11365123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care.
    Hippe E; Westin J; Wislöff F
    Eur J Haematol; 2005 Mar; 74(3):185-93. PubMed ID: 15693787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The process of clinical trials: a model for successful clinical trial participation.
    Lengacher CA; Gonzalez LL; Giuliano R; Bennett MP; Cox CE; Reintgen DS
    Oncol Nurs Forum; 2001 Aug; 28(7):1115-20. PubMed ID: 11517845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulating pharmaceutical innovation in the EU.
    Annemans L; Cleemput I; Hulstaert F; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):235-9. PubMed ID: 21671690
    [No Abstract]   [Full Text] [Related]  

  • 20. [European guideline for the quality of non-commercial clinical trials: elegant implementation in the Netherlands via the amended Dutch Medical Research Involving Human Subjects Act].
    Cohen AF
    Ned Tijdschr Geneeskd; 2003 Aug; 147(31):1493-5. PubMed ID: 12924078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.